Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
18 Results for "
TYK2 JH2 domain
" in MedChemExpress (MCE) Product Catalog:
Products (18)
18 Results for "TYK2 JH2 domain" in MCE Product Catalog:
35
35 Publications Verification
Synonyms: BMS-986165
1
1 Cited Publications
Synonyms: NDI-034858; TAK-279
Target:
Áreas de investigación:
Zasocitinib (NDI-034858) is a TYK2 inhibitor, target TYK2 JH2 domain with binding constant Kd of <200 pM .
1
1 Cited Publications
Target:
Áreas de investigación:
Tyk2-IN-5 (compound 6) is a potent, selective and orally active tyrosine kinase 2 (Tyk2) inhibitor that acts on the JH2 structural domain. Tyk2-IN-5 shows a Ki value of 0.086 nM for Tyk2 JH2 and an IC50 value of 25 nM for IFNα. Tyk2-IN-5 efficiently inhibits the production of IFNγ in a pharmacodynamic rat model and is fully efficacious in a rat model of arthritis .
Referencia número: HY-153701S
No. CAS: 2417135-66-9
Synonyms: Envudeucitinib; ESK-001
Target:
Áreas de investigación:
QL-1200186 is a selective, orally active, allosteric inhibitor targeting the tyrosine kinase TYK2 pseudokinase domain JH2 (IC50=0.06 nM, TYK2 JH2), with 164-fold selectivity over TYK1 JH2 (IC50=9.85 nM，TYK1 JH2). QL-1200186 first stabilizes the TYK2 JH2 conformation, inhibits the activity of the JH1 catalytic domain, and blocks the IFNα, IL-12/IL-23-mediated JAK-STAT signaling pathway. QL-1200186 can inhibit the production of Th1/Th17 cell-related cytokines (such as IFNγ, IL-23), reduce immune cell activation, and has no significant effect on JAK1/2/3 kinase activity. QL-1200186 can significantly improve skin inflammation in the Imiquimod (HY-B0180)-induced psoriasis mouse model and reduce the Psoriasis Area and Severity Index (PASI) score. QL-1200186 can be used in the study of autoimmune diseases such as psoriasis and systemic lupus erythematosus (SLE) .
Referencia número: HY-E70873
TYK2 is a member of the JAK family of non-receptor tyrosine kinases that act together with signal transducer and activator of transcription (STAT) factors in mediating intracellular signal transduction. JAKs are characterized by dual kinase domain: a tyrosine kinase domain (JH1) that is preceded by a pseudokinase domain (JH2). Tyk2(JH1/JH2) Recombinant Human Active Protein Kinase is a recombinant Tyk2(JH1/JH2) protein that can be used to study Tyk2(JH1/JH2)-related functions .
Synonyms: TYK2-IN-8
Áreas de investigación:
Fadeucravacitinib (Tyk2-IN-8) is an orally active selective TYK2 inhibitor with an IC50 of 5.7 nM against the JH2 pseudokinase domain. Fadeucravacitinib specifically binds to the TYK2 JH2 domain to exert allosteric inhibition, reduces JH1 kinase activity, and thereby blocks the TYK2/STAT pathway and pro-inflammatory signaling cascades. Fadeucravacitinib can be used in research related to inflammatory bowel disease .
Referencia número: HY-E70874
TYK2 is a member of the JAK family of non-receptor tyrosine kinases that act together with signal transducer and activator of transcription (STAT) factors in mediating intracellular signal transduction. JAKs are characterized by dual kinase domain: a tyrosine kinase domain (JH1) that is preceded by a pseudokinase domain (JH2). TYK2(JH2) Recombinant Human Active Protein Kinase is a recombinant TYK2(JH2) protein that can be used to study TYK2(JH2)-related functions .
Referencia número: HY-149892S
No. CAS: 2376999-19-6
Referencia número: HY-117287A
No. CAS: 1609392-28-0
Synonyms: BMS-986165 (hydrochloride)
Target:
Áreas de investigación:
Deucravacitinib (BMS-986165) hydrochloride is an orally active allosteric inhibitor of tyrosine kinase 2 (TYK2), with an IC50 of 0.2 nM and a Ki of 0.02 nM against the JH2 domain of TYK2, and it exhibits selectivity over other JAK subtypes and most of the kinome. Deucravacitinib hydrochloride blocks IL-23, IL-12, p-STAT1/3 and Type I IFN signaling, and inhibits Th17/Th1-mediated psoriasis inflammation . Deucravacitinib hydrochloride can be used in research related to moderate-to-severe plaque psoriasis, inflammatory bowel disease and systemic lupus erythematosus .
Referencia número: HY-163312S
No. CAS: 3018160-63-6
Referencia número: HY-181278
No. CAS: 1609529-70-5
Target:
Áreas de investigación:
Deucravacitinib analog 1 (compound 3), Deucravacitinib (HY-117287) derivative, is a TYK2 allosteric ligand. Deucravacitinib analog 1 binds to the JH2 domain of TYK2. Deucravacitinib analog 1 serves as a starting point for development of TYK2-targeting PROTAC degraders. Deucravacitinib analog 1 can be used for the researches of psoriasis and cancer .
Referencia número: HY-184833
No. CAS: 2417137-50-7
Áreas de investigación:
Tyk2-IN-25 is a TYK2 inhibitor that binds to the JH2 domain of TYK2. Tyk2-IN-25 inhibits p-STAT4 and p-STAT3 in human peripheral blood mononuclear cells. Tyk2-IN-25 is applicable to research related to multiple diseases such as immune and inflammatory diseases, and neurological diseases .
Referencia número: HY-E70872
TYK2 is a member of the JAK family of non-receptor tyrosine kinases that act together with signal transducer and activator of transcription (STAT) factors in mediating intracellular signal transduction. JAKs are characterized by dual kinase domain: a tyrosine kinase domain (JH1) that is preceded by a pseudokinase domain (JH2). TYK2(JH1) Recombinant Human Active Protein Kinase is a recombinant TYK2(JH1) protein that can be used to study TYK2(JH1)-related functions .
Referencia número: HY-111745R
No. CAS: 1797432-62-2
Target:
Áreas de investigación:
Tyk2-IN-5 (Standard) is the analytical standard of Tyk2-IN-5 (HY-111745). This product is intended for research and analytical applications. Tyk2-IN-5 (compound 6) is a potent, selective and orally active tyrosine Kinase 2 (Tyk2) inhibitor that acts on the JH2 structural domain. Tyk2-IN-5 shows a Ki value of 0.086 nM for Tyk2 JH2 and an IC50 value of 25 nM for IFNα. Tyk2-IN-5 efficiently inhibits the production of IFNγ in a pharmacodynamic rat model and is fully efficacious in a rat model of arthritis .
Referencia número: HY-187211
TYK2 activator-2 (Compound 6g) is a selective TYK2 activator and JAK3 inhibitor, with an EC50 of 0.21 μM against TYK2 and an IC50 of 1.2 μM against JAK3. TYK2 activator-2 destabilizes the JH2-JH1 autoinhibitory complex of TYK2, enhances the catalytic activity of TYK2, and inhibits the JH1 kinase domain activity of JAK3. TYK2 activator-2 can be used in cancer-related research .
Referencia número: HY-166594S
- 1
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
